PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, is making progress with CF102, the drug it develops for the treatment of liver cancer. Can-Fite reported today that an approval was granted by the Food and Drug Administration (FDA) to conduct a phase I study with its second pipeline drug, CF102.
